Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate. Strosberg, J. R., Wolin, E. M., Chasen, B., Kulke, M. H., Bushnell, D. L., Caplin, M. E., Baum, R. P., Kunz, P. L., Hobday, T. J., Hendifar, A., Oberg, K. E., Sierra, M., Kwekkeboom, D. J., Ruszniewski, P. B., Krenning, E. AMER SOC CLINICAL ONCOLOGY. 2016
View details for DOI 10.1200/jco.2016.34.4_suppl.194
View details for Web of Science ID 000378109600188